RxDoctor Payments Data

Zachery Baxter, MD

Urology · Santa Monica, CANPI 1538371679

Payments from drug & device makers

$2,843in general payments, 2019–2025

Across 98 payments — averaging $29.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • AbbVie$542
  • Rochester Medical Corporation$323
  • C. R. Bard, Inc. & Subsidiaries$255
  • Procept Biorobotics Corporation$249
  • BD$93
  • plus $245 from 8 others

What the payments were for

  • Grants$1214%
  • Food & beverage$2,72296%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)10$1,134
AbbVie27$542
Rochester Medical Corporation28$323
C. R. Bard, Inc. & Subsidiaries16$255
Procept Biorobotics Corporation3$249
BD5$93
Boston Scientific1$92
Progenics Pharmaceuticals, Inc.2$35
Sumitomo Pharma America, Inc.1$24
Coloplast1$23
ABC Home Medical Supply, Inc.1$20
Hollister Incorporated1$20
Urogen Pharma, Inc.1$17
Astellas Pharma US Inc1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,843 in reported general payments places this provider in the 50th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$306,232
Medicare patients
554
Services billed
13,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron198$184,641
MyrbetriqMirabegron199$160,514
Trospium Chloride331$24,652
Methenamine Hippurate224$18,527
Estradiol128$8,364
Mirabegron ErMirabegron12$5,390
Tamsulosin Hcl295$4,894
Fesoterodine Fumarate ErFesoterodine Fumarate28$4,182
Solifenacin Succinate48$3,155
Tolterodine Tartrate ErTolterodine Tartrate19$2,754
Imipramine Hcl73$2,247
Oxybutynin Chloride ErOxybutynin Chloride55$1,630
Silodosin11$1,531
Terazosin Hcl71$1,198
Alfuzosin Hcl ErAlfuzosin Hcl35$802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$24$184,641198 claims
Astellas Pharma US IncMyrbetriq$16$160,514199 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,324 urology providers in California.

Other urology in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →